Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024WEST LAFAYETTE, Ind., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 182nd on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. Inotiv’s revenue grew 448% from fiscal ye ...

WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on Wednesday, December 3, 2025, after the close of the stock market. The Company will h ...

Inotiv (NasdaqCM:NOTV) 2025 Conference November 18, 2025 11:00 AM ET Company ParticipantsDave Windley - Managing DirectorBob Leasure - CEODave WindleyGreat. Good morning, everybody. Appreciate the attendance here in the room. I'm Dave Windley at Jefferies with Jefferies Healthcare Equity Research. I'm based in the States. Again, thanks for your attendance here in the room and for those who may be listening online. Welcome to our 2025 London Healthcare Conference. It seems to grow and get tighter and tighter ...

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - Inotiv Inc (NASDAQ:NOTV) has an RSI of 26.7, with shares falling 33.2% to close at $0.69. The company anticipates fourth-quarter revenue between $137.5 million and $138.5 million, a 60% increase year-over-year in its Discovery and Safety Assessment services [3][8] - Airsculpt Technologies Inc (NASDAQ:AIRS) has an RSI of 29.3, with shares declining 23.8% to close at $4.17. The company reported lower-than-expected third-quarter results and reduced its FY25 revenue outlook, with a 60% drop in stock price over the past month [4][8] - Neuronetics Inc (NASDAQ:STIM) has an RSI of 23.9, with shares falling 17.1% to close at $1.65. The company cut its FY2025 sales guidance, experiencing a 40% decline in stock price over the past month [5][8]

Shares of Inotiv, Inc. (NOTV) jumped more than 23% in overnight trading after the company released preliminary results for its fiscal fourth quarter and full year ended September 30, 2025.The Indiana-based contract research organization, known for its nonclinical drug discovery and development services, expects Q4, 2025 revenue in the range of $137.5 million to $138.5 million, compared to $130.4 million in the prior year's fourth quarter - an increase of roughly 6% year-over-year.For the full fiscal year 2 ...

Core Insights - Several small-cap biotech and therapeutics companies experienced significant gains in after-hours trading, driven by earnings updates, financial guidance, and regulatory developments [1] Company Summaries - Inotiv, Inc. (NOTV) saw a 36.61% increase in after-hours trading to $0.94, recovering from a 33.20% decline at the close, following preliminary Q4 revenue expectations of $137.5 million to $138.5 million and full-year revenue projections of $512.5 million to $513.5 million [2] - Applied Therapeutics, Inc. (APLT) rose 16.89% to $0.33 after a 30.19% gain at the close, with investors reacting positively to a narrower Q3 net loss of $19.0 million, or $0.13 per share, compared to a $68.6 million loss, or $0.48 per share, in the same quarter last year [3] - Alumis Inc. (ALMS) advanced 7.09% to $5.97, despite reporting a Q3 net loss of $110.8 million, wider than the $93.1 million loss in the prior year, with $2.1 million in collaboration income potentially boosting investor confidence [4] - TELA Bio, Inc. (TELA) increased 7.89% to $1.23 after a 14.08% gain at the close, reporting a reduced Q3 net loss of $8.6 million compared to $10.4 million a year earlier, with revenue growth of 9% to $20.7 million and revised 2025 guidance projecting at least 16% revenue growth over 2024 [5] - Corcept Therapeutics Inc. (CORT) gained 4.90% to $78.80, reflecting continued investor interest despite no specific news released [6] - BioRestorative Therapies, Inc. (BRTX) jumped 8.06% to $1.34, rebounding from a 6.77% decline at the close, following the announcement of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application pathway for its BRTX-100 program [7]

Financial Results - Inotiv, Inc. announced preliminary unaudited financial results for Q4 and fiscal year ended September 30, 2025[4] - The press release detailing financial results is available in the Investors section of the Company's website[4] Upcoming Events - The presentation by CEO Robert Leasure at the Jefferies Global Healthcare Conference is scheduled for November 18, 2025[4]

Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare Conference WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and s ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA), urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Verrica may seek corporate governance reforms, the return of funds to the company, court-approved financial incentive awards, or other relief and benefits [2][3]. - Shareholder involvement is emphasized as a means to improve company policies, practices, and oversight mechanisms, ultimately enhancing shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Inotiv, Inc., urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Inotiv may seek corporate governance reforms, the return of funds to the company, court-approved financial incentive awards, or other relief and benefits [2][3]. - Shareholder involvement is emphasized as a means to improve company policies and practices, enhancing transparency and accountability, which can ultimately increase shareholder value [3]. Group 2: Legal Representation and Contingency Fees - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [2].